Acute promyelocytic leukemia. Management of the coagulopathy during daunorubicin-prednisone remission induction.
Seven adults with acute promyelocytic leukemia (APL) and disseminated intravascular coagulation were treated for remission induction with daunorubicin hydrochloride and prednisone. In all patients the coagulopathy was managed with continuous-infusion heparin sodium and vigorous transfusion with platelets, cryoprecipitate, and fresh frozen plasma. Five patients survived induction; they all achieved complete remission (CR). Median duration of CR was 27 + months; two patients presently survive in their initial CR at 28 and 48 months. Recognition of APL as a distinct type of acute leukemia and prompt initiation of treatment aimed at rapid cytoreduction and control of the coagulopathy has resulted in a prolonged disease-free survival for the majority of patients.
D000293:Adolescent; D000328:Adult; D001779:Blood Coagulation Factors; D001780:Blood Coagulation Tests; D011232:Chemical Precipitation; D003630:Daunorubicin / Q000627:therapeutic use*; D004211:Disseminated Intravascular Coagulation / Q000188:drug therapy / Q000209:etiology / Q000628:therapy*; D004359:Drug Therapy, Combination; D005260:Female; D006493:Heparin / Q000627:therapeutic use; D006801:Humans; D015470:Leukemia, Myeloid, Acute / Q000150:complications / Q000188:drug therapy* / Q000401:mortality; D008297:Male; D008875:Middle Aged; D010949:Plasma; D011241:Prednisone / Q000627:therapeutic use*; D012075:Remission, Spontaneous
D001779:Blood Coagulation Factors; D006493:Heparin; D011241:Prednisone; D003630:Daunorubicin